• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Esophagus >Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/ 5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis
【24h】

Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/ 5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis

机译：并发多西他赛/ CDDP / 5-FU（DCF）的新辅助化疗在食管鳞癌中的应用及近期预后

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Our aim in this study is to know whether clinical outcomes are improved by neoadjuvant chemotherapy (NAC) using Docetaxel/CDDP/5-FU (DCF) as compared to NAC using 5-FU/CDDP (FP). Methods Thirty-eight patients who underwent DCF NAC in cStage Will esophageal squamous cell carcinoma (ESCC) were compared with the 41 counterparts treated by FP NAC. Docetaxel and CDDP were both given to 70-75 mg/m2 with concurrent 5-FU at 750 mg/m2 in 3 cycles. Median follow-up term of DCF NAC reached 27 months. Results In DCF NAC, grade 3 adverse effects were recognized in 97 %, and completion rate of the DCF NAC was 86 %. In terms of PR + CR rate, DCF NAC was better (87 %) than FP NAC (59 %) (p = 0.005). Five year progression-free survival (PFS) and overall survival (OS) of FP NAC were 32 and 69 %, respectively, and OS of FP NAC was excellent putatively due to adoption of definitive chemoradiation therapy for recurrent diseases. Furthermore, survival was in favor of DCF NAC as compared to FP NAC for OS (p = 0.02) and PFS (p = 0.10), while R0 resection rate was similar. The 1st multivariate prognostic analysis among all cases with NAC revealed that significant factors were resectability and NAC modality for OS and PFS. We then performed the 2nd stage multivariate prognostic analysis limited to R0 cases including pathologic factors, which again identified DCF NAC modality as an independent prognostic factor. Conclusion DCF NAC for ESCC demonstrated high response rates, and may improve patient survival with acceptable feasibility.
机译：背景本研究的目的是了解与使用5-FU / CDDP（FP）的NAC相比，使用多西他赛/ CDDP / 5-FU（DCF）的新辅助化疗（NAC）能否改善临床结果。方法将38例行食管鳞癌的DCF NAC患者与41例接受FP NAC治疗的患者进行比较。多西他赛和CDDP均以70-75 mg / m2的剂量服用，并在3个周期内同时以750 mg / m2的剂量施用5-FU。 DCF NAC的中位随访期达到27个月。结果在DCF NAC中，识别出3级不良反应的发生率为97％，DCF NAC的完成率为86％。就PR + CR率而言，DCF NAC优于FP NAC（59％）（p = 0.005）。 FP NAC的五年无进展生存期（PFS）和总生存期（OS）分别为32％和69％，并且由于对复发性疾病采用了明确的化学放射疗法，因此FP NAC的OS极好。此外，与OS（p = 0.02）和PFS（p = 0.10）的FP NAC相比，DCF NAC的生存率更高，而R0切除率相似。在所有NAC病例中的第一项多因素预后分析显示，重要因素是OS和PFS的可切除性和NAC方式。然后，我们进行了仅限于R0病例（包括病理因素）的第二阶段多因素预后分析，这再次将DCF NAC方式确定为独立的预后因素。结论DCF NAC用于ESCC具有较高的反应率，并且可以以可接受的可行性改善患者生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号